Tigecycline is a broad-spectrum antibiotic designed to inhibit various types of bacteria, including Gram-positive, Gram-negative, anaerobic, and drug-resistant bacteria [1]. It is a glycylcycline antibiotic, a class of drugs that is a derivative of tetracyclines [1]. Tigecycline is used to treat a variety of infections, such as complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1].

The mechanism of action of tigecycline is through inhibition of bacterial protein synthesis [1]. It binds to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome, which ultimately inhibits bacterial protein synthesis [1].

Tigecycline has been shown to be effective against a wide range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae [1].

In summary, tigecycline is a broad-spectrum antibiotic that inhibits various types of bacteria, including Gram-positive, Gram-negative, anaerobic, and drug-resistant bacteria. It is used to treat a variety of infections and works by inhibiting bacterial protein synthesis.

Sources:
[1] DrugPatentWatch.com - Tigecycline (Tygacil) - Patent, Legal, and Clinical Information. <https://www.drugpatentwatch.com/drugs/tigecycline>